

# Agostino Chiaravalloti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6232330/publications.pdf>

Version: 2024-02-01

121  
papers

2,189  
citations

236925

25  
h-index

315739

38  
g-index

125  
all docs

125  
docs citations

125  
times ranked

3468  
citing authors

#	ARTICLE	IF	CITATIONS
1	Nocturnal Hypoxia and Sleep Fragmentation May Drive Neurodegenerative Processes: The Compared Effects of Obstructive Sleep Apnea Syndrome and Periodic Limb Movement Disorder on Alzheimer's Disease Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 127-139.	2.6	8
2	<sup>18</sup> F-FDG PET, cognitive functioning, and CSF biomarkers in patients with obstructive sleep apnoea before and after continuous positive airway pressure treatment. <i>Journal of Neurology</i> , 2022, 269, 5356-5367.	3.6	13
3	Complementary Role of Combined Indirect and Direct Cardiac Sympathetic (Hyper)Activity Assessment in Patients with Heart Failure by Spectral Analysis of Heart Rate Variability and Nuclear Imaging: Possible Application in the Evaluation of Exercise Training Effects. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 181.	1.6	4
4	Cognitive functioning, cerebrospinal fluid Alzheimer's disease biomarkers and cerebral glucose metabolism in late-onset epilepsy of unknown aetiology: A prospective study. <i>European Journal of Neuroscience</i> , 2022, 56, 5384-5396.	2.6	9
5	Comparison between diffusion-weighted magnetic resonance and positron-emission tomography in the evaluation of treated lymphomas with mediastinal involvement. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2022, 53, .	0.6	0
6	Awake breast cancer surgery: strategy in the beginning of COVID-19 emergency. <i>Breast Cancer</i> , 2021, 28, 137-144.	2.9	24
7	Molecular and metabolic imaging of castration-resistant prostate cancer: state of art and future prospects. <i>Current Molecular Medicine</i> , 2021, 21, .	1.3	1
8	Prognostic and Theranostic Applications of Positron Emission Tomography for a Personalized Approach to Metastatic Castration-Resistant Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3036.	4.1	10
9	Can chest imaging be used to draw information about body mass index and obesity status?. <i>Obesity Research and Clinical Practice</i> , 2021, 15, 187-190.	1.8	3
10	The role of <sup>18</sup> F-Fluorodeoxyglucose PET/CT in restaging patients with small cell lung cancer: a systematic review. <i>Nuclear Medicine Communications</i> , 2021, 42, 839-845.	1.1	3
11	Correlation of [ <sup>18</sup> F]florbetaben textural features and age of onset of Alzheimer's disease: a principal components analysis approach. <i>EJNMMI Research</i> , 2021, 11, 40.	2.5	3
12	High Basal Maximal Standardized Uptake Value (SUVmax) in Follicular Lymphoma Identifies Patients with a Low Risk of Long-Term Relapse. <i>Cancers</i> , 2021, 13, 2876.	3.7	1
13	Amyloid PET in the diagnostic workup of neurodegenerative disease. <i>Clinical and Translational Imaging</i> , 2021, 9, 383-397.	2.1	1
14	<sup>18</sup> F-FDOPA PET/CT SUV-Derived Indices and Volumetric Parameters Correlation in Patients with Primary Brain Tumors. <i>Cancers</i> , 2021, 13, 4315.	3.7	1
15	Medical Imaging in the Diagnosis of Schistosomiasis: A Review. <i>Pathogens</i> , 2021, 10, 1058.	2.8	5
16	Peptide Receptor Radionuclide Therapy and Primary Brain Tumors: An Overview. <i>Pharmaceuticals</i> , 2021, 14, 872.	3.8	7
17	Impact of COVID-19 Pandemic on Surgical Breast Cancer Patients Undergoing Neoadjuvant Therapy: A Multicentric Study. <i>Anticancer Research</i> , 2021, 41, 4535-4542.	1.1	7
18	Positron emission tomography imaging in primary brain tumors. , 2021, , .		0

#	ARTICLE	IF	CITATIONS
19	Tau Biomarkers in Dementia: Positron Emission Tomography Radiopharmaceuticals in Tauopathy Assessment and Future Perspective. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13002.	4.1	14
20	[18F] FBB cortical uptake is not related to the age of onset of Alzheimer's disease. <i>Nuclear Medicine Communications</i> , 2020, 41, 175-180.	1.1	2
21	10-Year Clinical Experience With 18F-Choline PET/CT. <i>Clinical Nuclear Medicine</i> , 2020, 45, 594-603.	1.3	6
22	Positron Emission Tomography (PET) and Neuroimaging in the Personalized Approach to Neurodegenerative Causes of Dementia. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7481.	4.1	16
23	Cortical metabolic changes and clinical outcome in normal pressure hydrocephalus after ventriculoperitoneal shunt: our preliminary results. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2020, 39, 367-374.	0.2	0
24	Levels and Factors Associated with Resilience in Italian Healthcare Professionals during the COVID-19 Pandemic: A Web-Based Survey. <i>Behavioral Sciences (Basel, Switzerland)</i> , 2020, 10, 183.	2.1	18
25	MGMT Promoter Methylation and IDH1 Mutations Do Not Affect [18F]FDOPA Uptake in Primary Brain Tumors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7598.	4.1	7
26	Lockdown of Breast Cancer Screening for COVID-19: Possible Scenario. <i>In Vivo</i> , 2020, 34, 3047-3053.	1.3	51
27	The potential of PSMA-targeted alpha therapy in the management of prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 823-829.	2.4	30
28	Delay in Breast Cancer Treatments During the First COVID-19 Lockdown. A Multicentric Analysis of 432 Patients. <i>Anticancer Research</i> , 2020, 40, 7119-7125.	1.1	61
29	Does Age Matter? Estimating Risks of Locoregional Recurrence After Breast-conservative Surgery. <i>In Vivo</i> , 2020, 34, 1125-1132.	1.3	17
30	Theranostic Aspects and Radioimmunotherapy in Pediatric Tumors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3849.	4.1	31
31	The Effect of Coronavirus (COVID-19) on Breast Cancer Teamwork: A Multicentric Survey. <i>In Vivo</i> , 2020, 34, 1685-1694.	1.3	42
32	Theranostic approaches in nuclear medicine: current status and future prospects. <i>Expert Review of Medical Devices</i> , 2020, 17, 331-343.	2.8	63
33	The Brain Metabolic Correlates of the Main Indices of Neuropsychological Assessment in Alzheimer's Disease. <i>Journal of Personalized Medicine</i> , 2020, 10, 25.	2.5	6
34	Radiological imaging in multiple myeloma: review of the state-of-the-art. <i>Neuroradiology</i> , 2020, 62, 905-923.	2.2	15
35	The role of epsilon phenotype in brain glucose consumption in Alzheimer's disease. <i>Annals of Nuclear Medicine</i> , 2020, 34, 254-262.	2.2	4
36	A rare case of pulmonary schistosomiasis: <sup>18</sup> F-fluorodeoxyglucose positron emission tomography/computed tomography findings. <i>Indian Journal of Nuclear Medicine</i> , 2020, 35, 336.	0.3	3

#	ARTICLE	IF	CITATIONS
37	Evaluation of Task-Related Brain Activity: Is There a Role for 18F FDG-PET Imaging?. BioMed Research International, 2019, 2019, 1-10.	1.9	12
38	Impact of Awake Breast Cancer Surgery on Postoperative Lymphocyte Responses. In Vivo, 2019, 33, 1879-1884.	1.3	32
39	Prostate cancer and inflammation: A new molecular imaging challenge in the era of personalized medicine. Nuclear Medicine and Biology, 2019, 68-69, 66-79.	0.6	19
40	Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 1. Critical Reviews in Oncology/Hematology, 2019, 140, 74-79.	4.4	18
41	Brain metabolic patterns in patients with suspected non-Alzheimer's pathophysiology (SNAP) and Alzheimer's disease (AD): is [18F] FDG a specific biomarker in these patients?. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1796-1805.	6.4	14
42	Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 2. Critical Reviews in Oncology/Hematology, 2019, 139, 117-124.	4.4	20
43	The role of molecular imaging in the frame of the revised dementia with Lewy body criteria. Clinical and Translational Imaging, 2019, 7, 83-98.	2.1	1
44	Cerebral glucose metabolism in idiopathic REM sleep behavior disorder is different from tau-related and $\alpha$ -synuclein-related neurodegenerative disorders: A brain [18F]FDG PET study. Parkinsonism and Related Disorders, 2019, 64, 97-105.	2.2	22
45	Overall survival and progression-free survival in patients with primary brain tumors after treatment: is the outcome of [18F] FDOPA PET a prognostic factor in these patients?. Annals of Nuclear Medicine, 2019, 33, 471-480.	2.2	14
46	The Role of 18F-FDG PET/CT in Staging and Prognostication of Mantle Cell Lymphoma: An Italian Multicentric Study. Cancers, 2019, 11, 1831.	3.7	18
47	Molecular Imaging in Pediatric Brain Tumors. Cancers, 2019, 11, 1853.	3.7	12
48	Prognostic and diagnostic value of [18F]FDG-PET/CT in restaging patients with small cell lung carcinoma. Nuclear Medicine Communications, 2019, 40, 808-814.	1.1	8
49	A patient with a benign and a malignant primary pulmonary meningioma: An evaluation with 18F fluorodeoxyglucose positron emission tomography/computed tomography and computed tomography with iodinated contrast. Indian Journal of Nuclear Medicine, 2019, 34, 45.	0.3	9
50	A rare case of primary uterine non-hodgkins's lymphoma with involvement of right ovary: Staging with 18F FDG PET/CT and iodinated contrast CT. Indian Journal of Nuclear Medicine, 2019, 34, 60.	0.3	0
51	Ageing effect on 18F-DOPA and 123I-MIBG uptake. Nuclear Medicine Communications, 2018, 39, 539-544.	1.1	1
52	Dopaminergic involvement in a drummer with focal dystonia: A case study. Clinical Neurology and Neurosurgery, 2018, 166, 54-55.	1.4	2
53	Coupled Imaging with [18F]FBB and [18F]FDG in AD Subjects Show a Selective Association Between Amyloid Burden and Cortical Dysfunction in the Brain. Molecular Imaging and Biology, 2018, 20, 659-666.	2.6	14
54	Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimer's disease patients: A CSF and FDG PET study. Brain Research, 2018, 1678, 116-122.	2.2	30

#	ARTICLE	IF	CITATIONS
55	Predictive and prognostic value of 18F-DOPA PET/CT in patients affected by recurrent medullary carcinoma of the thyroid. <i>Annals of Nuclear Medicine</i> , 2018, 32, 7-15.	2.2	17
56	Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 454-462.	1.6	169
57	Evaluation of the Usefulness of FDG-PET/CT for Nodal Staging of Breast Cancer. <i>Anticancer Research</i> , 2018, 38, 6639-6652.	1.1	25
58	Does fatigue in Parkinson's disease correlate with autonomic nervous system dysfunction?. <i>Neurological Sciences</i> , 2018, 39, 2169-2174.	1.9	7
59	Brain Imaging with Positron Emission Tomography: Novel Radiopharmaceuticals. <i>Current Medicinal Chemistry</i> , 2018, 25, 3060-3060.	2.4	0
60	Metabolic and Electrophysiological Changes Associated to Clinical Improvement in Two Severely Traumatized Subjects Treated With EMDR: A Pilot Study. <i>Frontiers in Psychology</i> , 2018, 9, 475.	2.1	5
61	Metformin and Autoimmunity: A "New Deal" of an Old Drug. <i>Frontiers in Immunology</i> , 2018, 9, 1236.	4.8	131
62	When Cognitive Decline and Depression Coexist in the Elderly: CSF Biomarkers Analysis Can Differentiate Alzheimer's Disease from Late-Life Depression. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 38.	3.4	25
63	Performance of FDG-PET/CT in solitary pulmonary nodule based on pre-test likelihood of malignancy: results from the ITALIAN retrospective multicenter trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1898-1907.	6.4	17
64	F-labeled radiopharmaceuticals for the molecular neuroimaging of amyloid plaques in Alzheimer's disease. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 8, 268-281.	1.0	19
65	Brain glucose consumption abnormalities in neuro-Behçet's disease: a preliminary 18F-FDG PET/CT study. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 148-149.	0.8	2
66	Cerebral metabolic changes related to clinical parameters in idiopathic anosmic patients during olfactory stimulation: a pilot investigation. <i>European Archives of Oto-Rhino-Laryngology</i> , 2017, 274, 2649-2655.	1.6	3
67	PET/CT with 18 F-choline: Physiological whole bio-distribution in male and female subjects and diagnostic pitfalls on 1000 prostate cancer patients. <i>Nuclear Medicine and Biology</i> , 2017, 51, 40-54.	0.6	49
68	Early cortical metabolic rearrangement related to clinical data in idiopathic sudden sensorineural hearing loss. <i>Hearing Research</i> , 2017, 350, 91-99.	2.0	16
69	Hypothalamic dysfunction is related to sleep impairment and CSF biomarkers in Alzheimer's disease. <i>Journal of Neurology</i> , 2017, 264, 2215-2223.	3.6	39
70	Functional correlates of TSH, fT3 and fT4 in Alzheimer disease: a F-18 FDG PET/CT study. <i>Scientific Reports</i> , 2017, 7, 6220.	3.3	20
71	Sleep apnoeas may represent a reversible risk factor for amyloid- $\beta^2$ pathology. <i>Brain</i> , 2017, 140, e75-e75.	7.6	23
72	Usefulness of 18F Flortbetaben in Diagnosis of Alzheimer's Disease and Other Types of Dementia. <i>Current Alzheimer Research</i> , 2017, 14, 154-160.	1.4	8

#	ARTICLE	IF	CITATIONS
73	PET Probe-Guided Surgery in Patients with Breast Cancer: Proposal for a Methodological Approach. In <i>Vivo</i> , 2017, 31, 101-110.	1.3	19
74	Subependymal spread of glioblastoma multiforme in positron emission tomography/computed tomography. <i>Indian Journal of Nuclear Medicine</i> , 2017, 32, 81.	0.3	0
75	Complement C3 Is the Strongest Predictor of Whole-Body Insulin Sensitivity in Psoriatic Arthritis. <i>PLoS ONE</i> , 2016, 11, e0163464.	2.5	13
76	La plasticità cerebrale correlata alle caratteristiche cliniche nella neuronite vestibolare acuta: una revisione della letteratura di neuroimaging. <i>Acta Otorinolaryngologica Italica</i> , 2016, 36, 75-84.	1.5	2
77	18F-DOPA PET/CT and MRI Findings in a Patient With Multiple Meningiomas. <i>Clinical Nuclear Medicine</i> , 2016, 41, 636-637.	1.3	6
78	Evaluation of recurrent disease in the re-staging of colorectal cancer by 18F-FDG PET/CT: Use of CEA and CA 19-9 in patient selection. <i>Oncology Letters</i> , 2016, 12, 4209-4213.	1.8	15
79	Comparison of 18F FDOPA PET, DSC-MRI and spectroscopy in a patient with brain metastatic lesions from lung cancer. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2016, 35, 207-208.	0.0	0
80	Cerebrospinal fluid lactate levels and brain [18F]FDG PET hypometabolism within the default mode network in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2040-2049.	6.4	73
81	Comparison between Early-Onset and Late-Onset Alzheimer's Disease Patients with Amnesic Presentation: CSF and 18F-FDG PET Study. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2016, 6, 108-119.	1.3	34
82	18F-DOPA PET/CT Physiological Distribution and Pitfalls. <i>Clinical Nuclear Medicine</i> , 2016, 41, 753-760.	1.3	28
83	Is cerebral glucose metabolism related to blood-brain barrier dysfunction and intrathecal IgG synthesis in Alzheimer disease?. <i>Medicine (United States)</i> , 2016, 95, e4206.	1.0	18
84	PET/CT with 18F-choline after radical prostatectomy in patients with PSA $\geq 2$ ng/ml. Can PSA velocity and PSA doubling time help in patient selection?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1418-1424.	6.4	27
85	Decoupled association between 18F-FDG and 18F-FDOPA uptake in a carcinoid of the thymus. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2016, 35, 139-140.	0.0	0
86	18F FDOPA uptake in brain metastasis of breast cancer. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2016, 35, 46-47.	0.0	0
87	Involvement of Subcortical Brain Structures During Olfactory Stimulation in Multiple Chemical Sensitivity. <i>Brain Topography</i> , 2016, 29, 243-252.	1.8	31
88	Quantitative analysis of basal and interim PET/CT images for predicting tumor recurrence in patients with Hodgkin's lymphoma. <i>Nuclear Medicine Communications</i> , 2016, 37, 16-22.	1.1	7
89	Autonomic Function Tests and $^{123}\text{I}$ -MIBG in Parkinson's Disease: Correlation to Disease Duration and Motor Symptoms. <i>CNS Neuroscience and Therapeutics</i> , 2015, 21, 727-732.	3.9	23
90	Low-dose CT and contrast-medium CT in hybrid PET/CT systems for oncologic patients. <i>Nuclear Medicine Communications</i> , 2015, 36, 867-870.	1.1	5

#	ARTICLE	IF	CITATIONS
91	Brain metabolic changes in Hodgkin disease patients following diagnosis and during the disease course: An 18F-FDG PET/CT study. <i>Oncology Letters</i> , 2015, 9, 685-690.	1.8	16
92	Factors affecting 18F FDOPA standardized uptake value in patients with primary brain tumors after treatment. <i>Nuclear Medicine and Biology</i> , 2015, 42, 355-359.	0.6	26
93	Cortical activity during olfactory stimulation in multiple chemical sensitivity: a 18F-FDG PET/CT study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 733-740.	6.4	33
94	Functional correlates of t-Tau, p-Tau and A $\beta$ 1-42 amyloid cerebrospinal fluid levels in Alzheimer's disease. <i>Nuclear Medicine Communications</i> , 2015, 36, 461-468.	1.1	22
95	Detection of local recurrence of prostate cancer after radical prostatectomy: Is there a role for early 18F-FCH PET/CT?. <i>Annals of Nuclear Medicine</i> , 2015, 29, 861-869.	2.2	6
96	Reply to comments by Laffon et al.: Liver SUV versus stage in Hodgkin's lymphoma: the total amount of uptake may play a role in the inverse relationship. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 166-166.	6.4	6
97	<sup>111</sup> In-Pentetreotide SPECT/CT in Pulmonary Carcinoid. <i>Anticancer Research</i> , 2015, 35, 4265-70.	1.1	3
98	The Role of PET [18F]FDOPA in Evaluating Low-grade Glioma. <i>Anticancer Research</i> , 2015, 35, 5117-22.	1.1	36
99	Initial Staging of Hodgkin's Disease. <i>Medicine (United States)</i> , 2014, 93, e50.	1.0	13
100	18F-Choline PET/CT Pitfalls in Image Interpretation. <i>Clinical Nuclear Medicine</i> , 2014, 39, 122-130.	1.3	77
101	Factors affecting inpatient liver and mediastinal blood pool 18F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin's lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1123-32.	6.4	29
102	WIDEN: A tool for medical image management in multicenter clinical trials. <i>Clinical Trials</i> , 2014, 11, 355-361.	1.6	22
103	Cerebellar metabolic involvement and its correlations with clinical parameters in vestibular neuritis. <i>Journal of Neurology</i> , 2014, 261, 1976-1985.	3.6	25
104	Do CSF levels of t-Tau, p-Tau and $\beta$ 1-42 amyloid correlate with dopaminergic system impairment in patients with a clinical diagnosis of Parkinson disease? A <sup>123</sup> I-FP-CIT study in the early stages of the disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 2137-2143.	6.4	13
105	A case of intracranial meningioma detected by 18F-choline PET/CT and examined by PET/MRI fusion imaging. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2014, 33, 306-307.	0.0	5
106	Transient parkinsonism after unilateral midbrain stroke: a compensatory intervention from the healthy side?. <i>Neurological Sciences</i> , 2014, 35, 2013-2015.	1.9	6
107	18F-FDG PET/MR in herpes simplex virus encephalitis: A case study. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2014, 33, 249-250.	0.0	4
108	Cortical Metabolic Arrangement During Olfactory Processing. <i>Medicine (United States)</i> , 2014, 93, e103.	1.0	6



#	ARTICLE	IF	CITATIONS
109	NI-11 * THE POTENTIAL ROLE OF 18F-FDOPA PET IMAGING IN THE EVALUATION OF LOW-GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2014, 16, v140-v140.	1.2	0
110	Cortico-subcortical metabolic correlates of olfactory processing in healthy resting subjects. <i>Scientific Reports</i> , 2014, 4, 5146.	3.3	14
111	The potential role of 18F-FDOPA PET imaging in low-grade gliomas.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2091-2091.	1.6	0
112	Does 123I-MIBG scintigraphy really assist the diagnosis of Parkinson's disease?. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 772-773.	2.2	10
113	Cardiac sympathetic denervation is not related to nigrostriatal degeneration in Parkinson's disease. <i>Annals of Nuclear Medicine</i> , 2013, 27, 444-451.	2.2	27
114	Is cerebral glucose metabolism affected by chemotherapy in patients with Hodgkin's lymphoma?. <i>Nuclear Medicine Communications</i> , 2013, 34, 57-63.	1.1	23
115	Evaluation of extraprostatic disease in the staging of prostate cancer by F-18 choline PET/CT. <i>Nuclear Medicine Communications</i> , 2013, 34, 733-740.	1.1	20
116	Early and Phasic Cortical Metabolic Changes in Vestibular Neuritis Onset. <i>PLoS ONE</i> , 2013, 8, e57596.	2.5	25
117	Molecular imaging of brain tumors with 18F-DOPA PET and PET/CT. <i>Nuclear Medicine Communications</i> , 2012, 33, 563-570.	1.1	34
118	Different patterns of cardiac sympathetic denervation in tremor-type compared to akinetic-rigid-type Parkinson's disease: Molecular imaging with 123I-MIBG. <i>Molecular Medicine Reports</i> , 2012, 6, 1337-1342.	2.4	24
119	Thalamic $^{18}\text{F}$ -FP-CIT uptake in a patient with clinical diagnosis of Parkinson's disease and depression. <i>Hellenic Journal of Nuclear Medicine</i> , 2012, 15, 74-5.	0.3	1
120	Different patterns of nigrostriatal degeneration in tremor type versus the akinetic-rigid and mixed types of Parkinson's disease at the early stages: Molecular imaging with 123I-FP-CIT SPECT. <i>International Journal of Molecular Medicine</i> , 2011, 28, 881-6.	4.0	21
121	Interim-PET Scan Interpretation In the Ongoing Prospective Clinical Trial HD 0607, In Advanced-Stage Hodgkin Lymphoma: Results of the the Expert Panel Review. <i>Blood</i> , 2010, 116, 3891-3891.	1.4	0